Literature DB >> 33529514

Comparison of the clinical differences between COVID-19, SARS, influenza, and the common cold: A systematic literature review.

Jacek Czubak1, Karolina Stolarczyk1, Anna Orzeł2, Marcin Frączek1, Tomasz Zatoński1.   

Abstract

BACKGROUND: This review focuses on the frequency of symptoms in COVID-19 in comparison to SARS, influenza and common cold.
OBJECTIVES: To evaluate and compare the knowledge about the clinical features, symptoms and differences between patients with COVID-19, SARS, influenza, and common cold. The research can help ear, nose and throat specialists and other health practitioners manage patients during the COVID-19 pandemic.
MATERIAL AND METHODS: The biomedical databases used in the study included PubMed and MEDLINE. Statistical analysis using the Z-score test assessed which symptoms were more characteristic of COVID-19 than other viral diseases.
RESULTS: Among individuals with COVID-19, the most frequently reported symptoms were cough (70%), fever (45%), muscular pain (29%), and headache (21%), whereas sore throat (12%), and rhinorrhea (4%) were observed at lower rates. Fever was identified as most frequent in COVID-19 (74%), appearing at a higher rate in those cases than in influenza (68%) or the common cold (40%) (p < 0.05). In comparison to other viral diseases, sore throat was rarely reported in COVID-19 and SARS (12% and 18%, respectively) (p < 0.05). In influenza and common cold, a cough was identified in 93% and 80% of cases (p < 0.05). Headache, rhinorrhea, muscular pain, and sore throat were more common in influenza (91%, 91%, 94%, and 84%, respectively) and common cold (89%, 81%, 94%, and 84%, respectively) than in COVID-19 (21%, 4%, 29%, and 12%, respectively) and SARS (45%, 12%, 55%, and 18%, respectively) (p < 0.05).
CONCLUSION: The results of the analysis show that a greater number of general symptoms should lead to a diagnosis of influenza or common cold rather than COVID-19.

Entities:  

Keywords:  COVID-19; ENT; SARS; common cold; influenza

Year:  2021        PMID: 33529514     DOI: 10.17219/acem/129573

Source DB:  PubMed          Journal:  Adv Clin Exp Med        ISSN: 1899-5276            Impact factor:   1.727


  6 in total

1.  Reply to "A limitation regarding the association between intranasal corticosteroid use and better COVID-19 outcomes: Nasal symptoms matter".

Authors:  Ronald Strauss; Amy H Attaway; Joe G Zein
Journal:  J Allergy Clin Immunol Pract       Date:  2022-01

2.  Patient experience of symptoms and impacts of COVID-19: a qualitative investigation with symptomatic outpatients.

Authors:  Diana Rofail; Nadine McGale; Anna J Podolanczuk; Alissa Rams; Krystian Przydzial; Sumathi Sivapalasingam; Vera Mastey; Patrick Marquis
Journal:  BMJ Open       Date:  2022-05-02       Impact factor: 3.006

3.  Epidemiologic Profile of Severe Acute Respiratory Infection in Brazil During the COVID-19 Pandemic: An Epidemiological Study.

Authors:  Nathália Mariana Santos Sansone; Matheus Negri Boschiero; Fernando Augusto Lima Marson
Journal:  Front Microbiol       Date:  2022-07-01       Impact factor: 6.064

4.  Anti-MDA5 Amyopathic Dermatomyositis-A Diagnostic and Therapeutic Challenge.

Authors:  Anca Bobirca; Cristina Alexandru; Anca Emanuela Musetescu; Florin Bobirca; Anca Teodora Florescu; Magdalena Constantin; Tiberiu Tebeica; Alesandra Florescu; Sebastian Isac; Mihai Bojinca; Ioan Ancuta
Journal:  Life (Basel)       Date:  2022-07-23

5.  Utilizing Baidu Index to Track Online Interest in Influenza During the COVID-19 Pandemic in China.

Authors:  Ziying He; Luyan Teng; Qinyi Tan
Journal:  Cureus       Date:  2022-08-01

6.  The significance of a lack of rhinorrhea in severe coronavirus 19 lung disease.

Authors:  Michael Eisenhut
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-06-01       Impact factor: 5.464

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.